ORIC Pharmaceuticals Future Growth
Future criteria checks 0/6
ORIC PharmaceuticalsDie Gewinne des Unternehmens werden voraussichtlich um 12.9% pro Jahr sinken, während die jährlichen Einnahmen um 58.7% pro Jahr steigen werden. Der Gewinn pro Aktie wird voraussichtlich decline um 2.1% pro Jahr steigen. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -48.1% betragen.
Key information
-5.1%
Earnings growth rate
3.2%
EPS growth rate
Biotechs earnings growth | 20.8% |
Revenue growth rate | 48.7% |
Future return on equity | -47.9% |
Analyst coverage | Good |
Last updated | 27 Mar 2024 |
Recent future growth updates
Recent updates
ORIC Pharmaceuticals: Mid-2024 Prostate Cancer Program Update Could Lead To Gains
Mar 13We're Not Very Worried About ORIC Pharmaceuticals' (NASDAQ:ORIC) Cash Burn Rate
Jan 18We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth
Sep 27ORIC Pharmaceuticals (NASDAQ:ORIC) Is In A Good Position To Deliver On Growth Plans
Jun 14Companies Like ORIC Pharmaceuticals (NASDAQ:ORIC) Are In A Position To Invest In Growth
Jan 24ORIC Pharmaceuticals: Poster Child For The Current Downturn In Biotech
Oct 14Is ORIC Pharmaceuticals (NASDAQ:ORIC) In A Good Position To Deliver On Growth Plans?
Oct 08ORIC Pharmaceuticals GAAP EPS of -$0.51 beats by $0.09
Aug 11ORIC Pharmaceuticals (NASDAQ:ORIC) Is In A Good Position To Deliver On Growth Plans
Jun 24We're Hopeful That ORIC Pharmaceuticals (NASDAQ:ORIC) Will Use Its Cash Wisely
Mar 08We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth
Nov 23We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth
Aug 05ORIC Pharmaceuticals EPS beats by $0.04
May 06Here's Why We're Not Too Worried About ORIC Pharmaceuticals' (NASDAQ:ORIC) Cash Burn Situation
Apr 16We're Hopeful That ORIC Pharmaceuticals (NASDAQ:ORIC) Will Use Its Cash Wisely
Jan 01Oric Pharma starts expansion phase of mid-stage solid tumor study with ORIC-101
Dec 21Oric Pharma prices stock offering at $23
Nov 13Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 11 | -175 | -149 | N/A | 6 |
12/31/2025 | N/A | -148 | -108 | -106 | 8 |
12/31/2024 | N/A | -121 | -78 | -78 | 9 |
12/31/2023 | N/A | -101 | -87 | -86 | N/A |
9/30/2023 | N/A | -93 | -78 | -77 | N/A |
6/30/2023 | N/A | -93 | -78 | -76 | N/A |
3/31/2023 | N/A | -90 | -75 | -73 | N/A |
12/31/2022 | N/A | -89 | -77 | -75 | N/A |
9/30/2022 | N/A | -91 | -78 | -76 | N/A |
6/30/2022 | N/A | -85 | -71 | -69 | N/A |
3/31/2022 | N/A | -85 | -69 | -67 | N/A |
12/31/2021 | N/A | -79 | -60 | -60 | N/A |
9/30/2021 | N/A | -84 | -62 | -61 | N/A |
6/30/2021 | N/A | -91 | -59 | -59 | N/A |
3/31/2021 | N/A | -81 | -53 | -52 | N/A |
12/31/2020 | N/A | -74 | -46 | -45 | N/A |
9/30/2020 | N/A | -54 | -35 | -35 | N/A |
6/30/2020 | N/A | -35 | -31 | -30 | N/A |
3/31/2020 | N/A | -30 | -27 | -26 | N/A |
12/31/2019 | N/A | -27 | -24 | -24 | N/A |
12/31/2018 | N/A | -21 | -21 | -21 | N/A |
Analyst Future Growth Forecasts
Einkommen vs. Sparrate: ORIC wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Ertrag vs. Markt: ORIC wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Hohe Wachstumserträge: ORIC wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Einnahmen vs. Markt: ORIC wird im nächsten Jahr voraussichtlich keine Einnahmen haben.
Hohe Wachstumseinnahmen: ORIC wird im nächsten Jahr voraussichtlich keine Einnahmen haben.
Earnings per Share Growth Forecasts
Future Return on Equity
Künftige Eigenkapitalrendite: ORIC wird voraussichtlich in 3 Jahren unrentabel sein.